A5089503365- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- Heat shock proteins research
- Protein Degradation and Inhibitors
- Endoplasmic Reticulum Stress and Disease
- Cancer Immunotherapy and Biomarkers
- Endometrial and Cervical Cancer Treatments
- HER2/EGFR in Cancer Research
- Genetics, Aging, and Longevity in Model Organisms
- Advanced Breast Cancer Therapies
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Intraperitoneal and Appendiceal Malignancies
- Lung Cancer Treatments and Mutations
- Melanoma and MAPK Pathways
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cancer Mechanisms and Therapy
- DNA Repair Mechanisms
- PI3K/AKT/mTOR signaling in cancer
- Economic and Financial Impacts of Cancer
- Lung Cancer Research Studies
University of Pennsylvania
2019-2025
Gynecologic Oncology Group
2016-2025
University of Pennsylvania Health System
2020-2024
Hospital of the University of Pennsylvania
2022-2024
Penn Center for AIDS Research
2024
Abramson Cancer Center
2024
UC San Diego Health System
2024
Fox Chase Cancer Center
2011-2023
Mersana Therapeutics (United States)
2022
UPMC Hillman Cancer Center
2020
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States and country’s fifth most common mortality women. A major challenge treating that patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating ovary, fallopian tube, or peritoneum, as these are all managed a similar manner. Most recommendations based on data with subtypes─high-grade serous grade 2/3 endometrioid. The also include specifically for less cancers,...
A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency drug delivery) plus carboplatin every 3 weeks or the addition bevacizumab to and administered has shown efficacy ovarian cancer. We proposed determine whether would prolong progression-free survival as compared with among patients receiving those not bevacizumab.
This selection from the NCCN Guidelines for Ovarian Cancer focuses on less common ovarian histopathologies (LCOHs), because new algorithms were added LCOHs and current revised 2016 update. The include clear cell carcinomas, mucinous grade 1 (low-grade) serous carcinomas/endometrioid epithelial carcinomas. also carcinosarcomas (malignant mixed Müllerian tumors of ovary), borderline (also known as low malignant potential tumors), sex cord-stromal tumors, germ tumors.
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations diagnosis, evaluation, treatment, and follow-up ovarian, fallopian tube, primary peritoneal cancers. These Insights summarize panel discussion behind recent important updates to guidelines, including revised guidance on alternative chemotherapy regimens advanced age and/or...
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate consisting a humanized anti-folate receptor alpha (FRα) monoclonal antibody linked to tubulin-disrupting maytansinoid DM4, in population patients with FRα-positive platinum-resistant ovarian cancer. Patients Methods epithelial ovarian, fallopian tube, or primary peritoneal cancer received IMGN853 at 6.0 mg/kg (adjusted ideal body weight)...
Purpose: Binding of colony-stimulating factor 1 (CSF1) ligand to the CSF1 receptor (CSF1R) regulates survival tumor-associated macrophages, which generally promote an immunosuppressive tumor microenvironment. AMG 820 is investigational, fully human CSF1R antibody that inhibits binding ligands and IL34 subsequent ligand-mediated activation. This first-in-human phase I study evaluated safety, pharmacokinetics, pharmacodynamics, antitumor activity 820.Experimental Design: Adult patients with...
Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in United States.We conducted phase 3, global, confirmatory, open-label, randomized, controlled trial to compare efficacy and safety MIRV with investigator's choice chemotherapy platinum-resistant, high-grade serous cancer. Participants who had previously received one three lines therapy high FRα tumor expression...
These NCCN Guidelines Insights focus on the major updates for 2012 Clinical Practice in Oncology (NCCN Guidelines) Ovarian Cancer by describing how and why new recommendations were made. The 6 update topics selected based recent important guidelines debate among panel members about clinical trials, include: 1) screening, 2) diagnostic tests assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) adjuvant bevacizumab combination with 5) therapy recurrent disease, 6)...
Adenocarcinoma of the endometrium (also known as endometrial cancer or more broadly uterine carcinoma corpus) is most common malignancy female genital tract in United States. An estimated 49,560 new cases will occur 2013, with 8190 deaths resulting from disease. Uterine sarcomas (stromal/mesenchymal tumors) are uncommon malignancies, accounting for approximately 3% all cancers. The NCCN Guidelines Neoplasms describe malignant epithelial carcinomas and sarcomas; each these major categories...
Based on evidence of human papillomavirus (HPV)-induced immune evasion, immunotherapy may be an attractive strategy in cervical cancer. Ipilimumab is a fully humanized monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4), which acts to downregulate the T-cell response.To assess safety and antitumor activity ipilimumab recurrent cancer.A multicenter trial was designed for patients with metastatic cancer (squamous cell carcinoma or adenocarcinoma) measurable disease...
These NCCN Clinical Practice Guidelines in Oncology for Cervical Cancer focus on early-stage disease, because it occurs more frequently the United States. After careful clinical evaluation and staging, primary treatment of cervical cancer is either surgery or radiotherapy. guidelines include fertility-sparing non-fertility-sparing those with which disease confined to uterus. A new algorithm was added select patients stage IA IB1 disease..
The inhibitor of apoptosis (IAP) family antiapoptotic proteins has been identified as a target for small molecule inhibitors in cancer. Second mitochondrial-derived activator caspases (SMAC) efficiently and naturally antagonizes IAPs, preclinical studies have determined that SMAC mimetics potent anticancer properties. Here, we report first-in-human trial designed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics/pharmacodynamics (PK/PD) birinapant, novel mimetic....
To characterize folate receptor alpha (FRα) expression in archival and fresh biopsy tumor samples from relapsed ovarian cancer patients.
Purpose: Recent studies have demonstrated increasing rates of financial toxicities and emotional distress related to cancer treatment. This study assessed characterized the relationships among distress, symptoms, overall in patients with cancer. Methods: A cross-sectional sample who visited our outpatient medical oncology psychiatry clinics completed a pen-and-paper survey. The survey demographics; cost concerns; financial, emotional, distress. Results: One hundred twenty insured Sixty-five...
ObjectivePlatinum-resistant, high-grade serous ovarian cancer (HGSOC) has limited treatment options. Preclinical data suggest that poly(ADP-ribose) polymerase inhibitors (PARPi) and ataxia telangiectasia Rad3-related kinase (ATRi) are synergistic. CAPRI (NCT03462342) is an investigator-initiated study of olaparib plus ceralasertib in recurrent HGSOC. Herein, we present results from the platinum-resistant cohort.MethodsA Simon 2-stage design was utilized. Platinum-resistant HGSOC patients...
In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMination rate constant K [KELIM] score) was predictive biomarker. Only high-risk disease (suboptimally resected stage III, or IV) exhibiting KELIM score < 1.0 had overall survival (OS) benefit from (median: 29.7
Addition of ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) to PARP (PARPi) overcomes PARPi resistance in high-grade serous ovarian cancer (HGSOC) cell mouse models. We present the results an investigator-initiated study combination (olaparib) ATRi (ceralasertib) patients with acquired PARPi-resistant HGSOC.Eligible had recurrent, platinum-sensitive BRCA1/2 mutated or homologous recombination (HR)-deficient (HRD) HGSOC clinically benefited from (response by imaging/CA-125...
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations this disease. These Insights detail how the evolution of use PARP inhibitors as maintenance single-agent regimens ovarian cancer informed panel in guidelines.
Objective Evaluate the antitumor activity and safety profile of triplet combination mirvetuximab soravtansine (MIRV), carboplatin, bevacizumab in recurrent, platinum-sensitive ovarian cancer. Methods Participants with epithelial ovarian, fallopian tube, or primary peritoneal cancer (1–2 prior lines therapy) received MIRV (6 mg/kg adjusted ideal body weight), carboplatin (AUC5), (15 mg/kg) once every 3 weeks. Carboplatin could be discontinued after 6 cycles per investigator discretion;...
In 2008, an estimated 62,480 new cases of melanoma will have been diagnosed and approximately 8420 patients died the disease in United States. 1 However, these projections for may represent a substantial underestimation, because many superficial situ melanomas treated outpatient setting are not reported.The incidence continues to increase dramatically.Melanoma is increasing men more rapidly than any other malignancy women except lung cancer.For someone born States 2005, lifetime risk...
Two strategies to interrogate the insulin growth factor 1 receptor (IGF-1R) pathway were investigated: vertical inhibition with dalotuzumab and MK-2206 or ridaforolimus potentiate PI3K targeting horizontal cross-talk MK-0752 exert effects against cellular proliferation, angiogenesis, stem cell propagation. A phase I, multi-cohort dose escalation study was conducted in patients advanced solid tumours. Patients received (10 mg kg–1) escalating doses of (90–200 mg) (7.5–10 (1800 weekly. Upon...